You are here

Pepsi or Coke? Influence of acid on dasatinib absorption

David Fitz's picture
Submitted by David Fitz on Tue, 21/08/2018 - 5:23pm

Dasatinib's bioavailability is highly dependent on gastric pH. When proton-pump inhibitors (PPIs) are co-administered with dasatinib, absorption is significantly reduced. Cola intake at the time of drug administration has been demonstrated to lead to relevant increases in the bioavailability for other acid labile drugs during PPI treatment. This manuscript reviews the relevant literature supporting a strategy of temporarily lowering the gastric pH with a carbonated beverage at the time of drug administration.

UK CML Patient Conference 2018 (22 Sept): Video Recordings Now Available

David Fitz's picture
Submitted by David Fitz on Tue, 14/08/2018 - 4:40pm

The UK CML Patient Conference: '22/09 World CML Day' Saturday 22nd September 2018.

The event has now taken place, and video recordings of the main presentations are available on this page.

Click on the link in each agenda item to view the corresponding presentation.


AGENDA

Chronic Myeloid Leukaemia Patient Day. Saturday 22nd September 2018 'World CML Day'.

Organised by Professor Mhairi Copland on behalf of the NCRI CML Sub-Group.

Chronic myeloid leukemia and pregnancy: patient and partner perspectives

sandy craine's picture
Submitted by sandy craine on Sun, 29/07/2018 - 5:12pm

Marlise R. Luskin Published online: 23 Jul 2018

As CML is now a controllable, chronic condition for most patients, focus turns to the impact of the disease and TKI treatment on quality of life. For young patients with CML, the opportunity to raise a family is a frequent goal. However, the TKIs that have dramatically improved CML outcomes are teratogenic, meaning that women with CML who want to conceive or who become pregnant must stop their TKI which may, in turn, comprise treatment of the CML.

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors

sandy craine's picture
Submitted by sandy craine on Mon, 09/07/2018 - 2:21pm

"There are preliminary data that CML patients who maintain TFR successfully after TKI cessation have higher NK cell numbers and function compared with those who relapse off-treatment, further supporting the importance of recrudescence of effector-mediated immune surveillance for achieving sustained TFR in CML"....."When successful TKI therapy reduces the leukemic cell load, suppressor cell activity, and PD-1 expression, there is consequent reactivation of the immune effector response"

Early Results of Lower Dose Dasatinib (50 mg Daily) as Frontline Therapy

sandy craine's picture
Submitted by sandy craine on Sat, 05/05/2018 - 3:17pm

"At a median follow-up of 9 months, 60 patients were evaluable for a response at 3 months. The rates of patients achieving BCR-ABL1 transcript levels 􏰀 10% and 􏰀 1% at 3 months by the International Standard were 93% and 72%, respec- tively. The rates of complete cytogenetic response by conventional cytogenetics or fluorescence in situ hybridization at 6 and 12 months were 86% and 88%, respectively.

Long-Term Outcome Of Nilotinib 400 Mg Twice Daily In First-Line Treatment

sandy craine's picture
Submitted by sandy craine on Tue, 27/02/2018 - 10:56am

Nilotinib is a second-generation TKI that has been approved for the first-line treatment of chronic-phase chronic myeloid leukemia, based on the results of a prospective randomized study of nilotinib vs imatinib (ENESTnd). Apart from this registration study, very few data are currently available on first-line nilotinib treatment. We report here the long-term, 6-year results of the first investigator-sponsored, GIMEMA multicenter phase 2, single-arm trial with nilotinib 400 mg twice daily as first-line treatment in 73 patients with cp CML

Once a day nilotinib: A Real Life Observational Study

sandy craine's picture
Submitted by sandy craine on Fri, 22/12/2017 - 5:25pm

Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED)

 

Delphine Rea, MD1, Jean-Michel Cayuela, PhD2*, Stephanie Dulucq, PhD3* and Gabriel Etienne, MD, PhD4*


Introduction

Pages